Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

Publisher: John Wiley & Sons Inc

E-ISSN: 1097-0142|124|2|306-314

ISSN: 0008-543x

Source: CANCER, Vol.124, Iss.2, 2018-01, pp. : 306-314

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract